SMN2 and proximal spinal muscular atrophy: The SPR1NT (NCT03505099) study was a multicenter, open-label, phase 3, a trial evaluating the safety and efficacy of onasemnogene abeparvovec in presymptomatic SMA infants who have two to three copies of the SMN2 gene.